| DC Field | Value | Language |
|---|
| dc.contributor.author | Graiqevci-Uka, V. | - |
| dc.contributor.author | Behluli, E. | - |
| dc.contributor.author | Hadziselimovic, R. | - |
| dc.contributor.author | Liehr, T. | - |
| dc.contributor.author | Temaj, G. | - |
| dc.date.accessioned | 2024-08-23T08:16:42Z | - |
| dc.date.available | 2024-08-23T08:16:42Z | - |
| dc.date.issued | 2024 | - |
| dc.identifier.citation | Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia / V. Graiqevci-Uka, E. Behluli, R. Hadziselimovic [et al.] // Research Results in Pharmacology. - 2024. - Vol.10, №2.-P. 27-39. - Doi: 10.18413/rrpharmacology.10.382. - Refer.: p. 34-38. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/63421 | - |
| dc.description.abstract | Acute lymphoblastic leukemia (ALL) is the most frequent pediatric leukemia; it can be defined according to chromosomic and genomic data. Cytogenetic analyses and determination of chromosomal numbers (such as hypo- or hyperdiploidy) and/or specific chromosomal rearrangements are basic for ALL classification and treatment | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | B-ALL | ru |
| dc.subject | T-ALL | ru |
| dc.subject | Ph-Like ALL | ru |
| dc.subject | methotrexate | ru |
| dc.subject | 6-mercaptopurine | ru |
| dc.subject | acute lymphoblastic leukemia | ru |
| dc.title | Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 10, № 2
|
